Reports
Sale
Pneumococcal Vaccine Market Size, Trends, Report, Forecast: By Vaccine Type: Conjugate vaccine, Polysaccharide vaccine; By Product Type: Prevnar 13, Synflorix, neumovax23; By Distribution Channel: Distribution partner companies, Non-governmental Organizations, Government Authorities; Regional Analysis; Supplier Landscape; 2024-2032
Pneumococcal Vaccine Market Outlook
The pneumococcal vaccine market size was valued at USD 8.61 million in 2023, driven by the emphasis on preventing invasive pneumococcal disease like pneumonia and meningitis across the 7 major markets. The market is expected to grow at a CAGR of 4.9% during the forecast period of 2024-2032, with the values likely to rise from USD 9.03 million in 2024 to USD 13.21 million by 2032.
Pneumococcal Vaccine: Introduction
Pneumococcal vaccine is used to prevent pneumococcal disease, which is caused by the Streptococcus pneumoniae bacteria. This bacterium colonises the human respiratory tract and can induce both invasive (such as pneumonia, meningitis, bacteraemia) and non-invasive diseases (such as acute otitis media and sinusitis). Invasive diseases can even to hospitalisation and morbidity in patients.
There are two common types of pneumococcal vaccines used, namely pneumococcal conjugate vaccines (PCVs, specifically PCV15 and PCV20) and pneumococcal polysaccharide vaccine (PPSV23). PCV13 or PCV15 is commonly recommended to children younger than 2 years of age.
Pneumococcal Vaccine Market Analysis
Pneumonia accounts for 14% of children’s deaths aged 5 years or younger. To curb this burden of mortality rates, researchers have been working towards effective vaccine solutions for infants and children. In April 2023, Pfizer’s 20-valent pneumococcal conjugate vaccine, PREVNAR 20®, received FDA approval. This vaccine offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine. It is built on PREVAR 13 and contains seven additional serotypes, related to antibiotic resistance and increased diseases severity.
The pneumococcal vaccine market value is also expected to grow with continuous advancements in the existing vaccines. Pneumovax 23™ by Merck helps against fighting 23 types of pneumococcal bacteria. In August 2023, Merck revealed that their investigational 21-valent PCV called V116 showcased significant immune responses in Phase 3 trials. It was applied on both, previously vaccinated and vaccine-naïve adults.
In April 2023, Vaxcyte reported that their 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, designed specifically for patients 65 years or older showed positive data from the phase 2 study.
The technology used to create vaccines is experiencing a transition especially during the COVID-19 era. Researchers have started using novel techniques like ‘Multiple Antigen Presenting System’, or MAPS to create vaccines. This also indicates that the pneumococcal vaccine market demand will grow with the arrival of improved vaccines for quality treatment in patients.
Pneumococcal Vaccine Market Segmentation
Market Breakup by Vaccine Type
- Conjugate vaccine
- Polysaccharide vaccine
Market Breakup by Product Type
- Prevnar 13
- Synflorix
- neumovax23
Market Breakup by Distribution Channel
- Distribution partner companies
- Non-governmental Organizations
- Government Authorities
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Pneumococcal Vaccine Market Overview
The United States, with a well-developed infrastructure and being home to prominent healthcare companies, has dominated the pneumococcal vaccine market share in the historic period. With awareness campaigns and initiatives set up government and healthcare institutions, the population has become more accepting towards vaccinations. This has led to better vaccination rates in the region. In addition, the COVID-19 outbreak has made human bodies more susceptible to respiratory diseases, therefore, the demand for pneumococcal vaccine has surged.
Europe is expected to lead the market with the growing research and developments in the healthcare system. In April 2023, Spain hosted the 2nd Global Forum on childhood pneumonia which focused on preventing the fatal disease by providing vaccinations and medications to middle and low-income countries.
The Asia Pacific region is projected to have the highest pneumococcal vaccine market growth with several government initiatives to make the population undertake vaccinations. One such initiative is the SAANS (Social Awareness and Action to Neutralise Pneumonia Successfully) campaign by the Indian government, which spreads information on pneumonia prevention. Moreover, the region is also developing a robust infrastructure that supports advanced medical research and development for improved patient outcomes.
Pneumococcal Vaccine Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- GlaxoSmithKline, Plc.
- Sanofi
- Merck & Co.
- Panacea Biotech
- Pfizer Inc
- PnuVax Incorporated
- SK bioscience
- Walvax Biotechnology Co.
- Beijing Minhai Biotechnology Co.
- Serum Institute of India
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Vaccine Type |
|
| Breakup by Product Type |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Pneumococcal Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Pneumococcal Disease Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Pneumococcal Disease Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Pneumococcal Disease Epidemiology Forecast (2017-2032)
5.3.1 Germany Pneumococcal Disease Epidemiology Forecast (2017-2032)
5.3.2 France Pneumococcal Disease Epidemiology Forecast (2017-2032)
5.3.3 Italy Pneumococcal Disease Epidemiology Forecast (2017-2032)
5.3.4 Spain Pneumococcal Disease Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Pneumococcal Disease Epidemiology Forecast (2017-2032)
5.4 Japan Pneumococcal Disease Epidemiology Forecast (2017-2032)
6 Pneumococcal Vaccine Market Overview – 7MM
6.1 Pneumococcal Vaccine Market Historical Value (2017-2023)
6.2 Pneumococcal Vaccine Market Forecast Value (2024-2032)
7 Pneumococcal Vaccine Market Landscape – 7MM
7.1 Pneumococcal Vaccine: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Pneumococcal Vaccine Product Landscape
7.2.1 Analysis by Vaccine Type
7.2.2 Analysis by Product Type
8 Pneumococcal Vaccine Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Pneumococcal Vaccine Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Pneumococcal Vaccine Market Segmentation – 7MM
11.1 Pneumococcal Vaccine Market by Vaccine Type
11.1.1 Market Overview
11.1.2 Conjugate vaccine
11.1.3 Polysaccharide vaccine
11.2 Pneumococcal Vaccine Market by Product Type
11.2.1 Market Overview
11.2.2 Prevnar 13
11.2.3 Synflorix
11.2.4 neumovax23
11.3 Pneumococcal Vaccine Market by Distribution Channel
11.3.1 Market Overview
11.3.2 Distribution partner companies
11.3.3 Non-governmental Organizations
11.3.4 Government Authorities
11.4 Pneumococcal Vaccine Market by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.4.4 Japan
12 United States Pneumococcal Vaccine Market
12.1 Pneumococcal Vaccine Market Historical Value (2017-2023)
12.2 Pneumococcal Vaccine Market Forecast Value (2024-2032)
12.3 Pneumococcal Vaccine Market by Vaccine Type
12.4 Pneumococcal Vaccine Market by Product Type
13 EU-4 and United Kingdom Pneumococcal Vaccine Market
13.1 Pneumococcal Vaccine Market Historical Value (2017-2023)
13.2 Pneumococcal Vaccine Market Forecast Value (2024-2032)
13.3 Germany Pneumococcal Vaccine Market Overview
13.3.1 Pneumococcal Vaccine Market by Vaccine Type
13.3.2 Pneumococcal Vaccine Market by Product Type
13.4 France Pneumococcal Vaccine Market Overview
13.4.1 Pneumococcal Vaccine Market by Vaccine Type
13.4.2 Pneumococcal Vaccine Market by Product Type
13.5 Italy Pneumococcal Vaccine Market Overview
13.5.1 Pneumococcal Vaccine Market by Vaccine Type
13.5.2 Pneumococcal Vaccine Market by Product Type
13.6 Spain Pneumococcal Vaccine Market Overview
13.6.1 Pneumococcal Vaccine Market by Vaccine Type
13.6.2 Pneumococcal Vaccine Market by Product Type
13.7 United Kingdom Pneumococcal Vaccine Market Overview
13.7.1 Pneumococcal Vaccine Market by Vaccine Type
13.7.2 Pneumococcal Vaccine Market by Product Type
14 Japan Pneumococcal Vaccine Market
14.1 Pneumococcal Vaccine Market Historical Value (2017-2023)
14.2 Pneumococcal Vaccine Market Forecast Value (2024-2032)
14.3 Pneumococcal Vaccine Market by Vaccine Type
14.4 Pneumococcal Vaccine Market by Product Type
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 GlaxoSmithKline, Plc.
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Sanofi
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Merck & Co.
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Panacea Biotech
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Pfizer Inc
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 PnuVax Incorporated
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 SK bioscience
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Walvax Biotechnology Co.
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Beijing Minhai Biotechnology Co.
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Serum Institute of India
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
22 Pneumococcal Vaccine Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 8.61 million in 2023, driven by the focus on preventing diseases like meningitis, pneumonia, and others with the help of vaccinations.
The market is anticipated to grow at a CAGR of 4.9% during the forecast period of 2024-2032, likely to reach a market value of USD 13.21 million by 2032.
Vaccine producing technology has evolved post COVID-19. Scientists have turned to different approaches to improve the vaccine efficacy. As a result, the market demand has increased with the arrival of customised and enhanced vaccines.
The current market trend includes the arrival of vaccinations for all age groups, spanning from infants to older people. Pfizer’s PREVNAR 20®, an infant PVC received FDA approval in April 2023, whereas Vaxcyte’s VAX-24, designed for patients 65 years or older showed positive data from a phase 2 study.
The major regions of the market include United States, Japan, EU-4 and the United Kingdom. EU-4 includes Germany, France, Italy, and Spain.
Conjugate vaccine and polysaccharide vaccine are commonly used vaccine type.
Product types include Prevnar 13, Synflorix and neumovax23.
Major distribution channels include distribution partner companies, non-governmental organizations, and government authorities.
Key players involved in the market are GlaxoSmithKline, Plc., Sanofi, Merck & Co., Panacea Biotech, Pfizer Inc., PnuVax Incorporated, SK bioscience, Walvax Biotechnology Co., Beijing Minhai Biotechnology Co., and Serum Institute of India.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER